Dorte Lisbet Nielsen

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Inna Markovna Chen · 12 shared papers, 2019–2025 · strength 2.04
   • Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
2. Julia Sidenius Johansen · 10 shared papers, 2021–2025 · strength 1.72
   • Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
3. Susann Theile · 8 shared papers, 2022–2025 · strength 1.50
   • Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
   • Paper Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic du… DOI 10.1016/j.esmoop.2024.103489↗
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
4. Sidsel C. Lindgaard · 4 shared papers, 2021–2024 · strength 0.67
   • Paper Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic du… DOI 10.1016/j.esmoop.2024.103489↗
   • Paper Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. DOI 10.1002/cam4.5240↗
   • Paper Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing… DOI 10.3390/cancers14133250↗
5. Astrid Zedlitz Johansen · 3 shared papers, 2022–2023 · strength 0.51
   • Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
   • Paper Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. DOI 10.1002/cam4.5240↗
   • Paper Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing… DOI 10.3390/cancers14133250↗
6. Carsten Palnæs Hansen · 3 shared papers, 2021–2023 · strength 0.46
   • Paper Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. DOI 10.1002/cam4.5240↗
   • Paper A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therap… DOI 10.3390/pharmaceutics14030509↗
   • Paper Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. DOI 10.1158/1078-0432.ccr-20-4215↗
7. Katherine R. Pelz · 2 shared papers, 2025 · strength 0.41
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
8. Denis C. Guttridge D · 2 shared papers, 2025 · strength 0.41
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
9. Leonidas G. Koniaris · 2 shared papers, 2025 · strength 0.41
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
10. Teresa A Zimmers · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
11. Olav Faisal Dajani · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
12. Michael C. Ostrowski · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
13. Estrid Vilma Solyom Høgdall · 2 shared papers, 2023–2025 · strength 0.41
    • Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
    • Paper Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗
14. Jessica Xin Hjaltelin · 2 shared papers, 2022–2023 · strength 0.31
    • Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
    • Paper Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗
15. Søren Brunak · 2 shared papers, 2022–2023 · strength 0.31
    • Paper Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
    • Paper Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗
16. I.M. Chen · 1 shared paper, 2024 · strength 0.22
    • Paper Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic du… DOI 10.1016/j.esmoop.2024.103489↗
17. Troels Dreier Christensen · 1 shared paper, 2024 · strength 0.22
    • Paper Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic du… DOI 10.1016/j.esmoop.2024.103489↗
18. Rasmus Erik Johansson Mortensen · 1 shared paper, 2023 · strength 0.17
    • Paper Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhib… DOI 10.1136/jitc-2022-006432↗
19. Mads Hald Andersen · 1 shared paper, 2023 · strength 0.17
    • Paper Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhib… DOI 10.1136/jitc-2022-006432↗
20. Andreas H. Henriksen · 1 shared paper, 2019 · strength 0.14
    • Paper Checkpoint inhibitors in pancreatic cancer. DOI 10.1016/j.ctrv.2019.06.005↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.